Prot# MT-1186-A02: A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

Project: Research project

Project Details

Effective start/end date3/16/213/16/24


  • ICON Clinical Research, LLC (MT-1186-A02 // MT-1186-A02)
  • Mitsubishi Tanabe Pharma America, Inc. (MT-1186-A02 // MT-1186-A02)